Expert Q&As
Launching in EU - Q&A 8
What risk areas should we pay special attention to (pharmacovigilance, legal, compliance, etc.) when launching in Europe?
Access decades of experience
What’s Inside the Q&A:
Pharmacovigilance Systems
Uncover how Europe’s safety oversight demands transform the way you monitor, report, and protect patient outcomes.
Legal and Liability Frameworks
Explore the intersecting layers of EU law that reshape your approach to contracts, privacy, and product responsibility.
Compliance and Ethics Culture
See how embedding transparency and integrity from day one becomes your strongest shield against regulatory risk.
Reputation and Risk Management
Learn how strategic communication and preparedness safeguard both your market access and public trust.
Download our expert answer
Discover our latest news
Expert Q&As
First interactions with EMA - Q&A 7
What regulatory pathway missteps should we avoid, and how can we streamline our EU dossier preparation?
Expert Q&As
Launching in EU - Q&A 9
Should we launch ourselves in Europe or consider partnering/outlicensing, and how do we decide?
Expert Q&As
First interactions with EMA - Q&A 2
How does the EU drug development landscape differ from the US ?
